INmune BioINMB -4.59%52 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates INMB with a GF Score™ of 52/100 and a GF Value™ of $1.84 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, INmune Bio ranks worse than 105820% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. INmune Bio's EBITDA for the
three
months ended in Mar. 2026 was $-5.76 Mil. INmune Bio's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, INmune Bio's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
INmune Bio (NAS:INMB) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
INmune Bio EBITDA Margin % Related Terms
INmune Bio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for INmune Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INMB vs GRDX, VERU, ABVC: EBITDA Margin % Comparison
For the Biotechnology subindustry, INmune Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INmune Bio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, INmune Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where INmune Bio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INmune Bio (INMB) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on INmune Bio and its competitors. According to the industry distribution chart, INmune Bio ranks #999999 out of 945 companies in the Biotechnology industry.
Is INmune Bio's EBITDA Margin % too high?
INmune Bio's current EBITDA Margin % is 0.00%. Based on the distribution chart, INmune Bio ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, INmune Bio has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's EBITDA Margin % compare to GRDX and VERU?
According to the Biotechnology industry distribution chart, INmune Bio ranks #999999 out of 945 companies for EBITDA Margin %. This places INmune Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on INmune Bio and its competitors. INmune Bio's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.84, compared to a current price of $1.36 — trading 26.4% below its estimated fair value. The current EBITDA Margin % is 0.00%. INmune Bio's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For INmune Bio (INMB), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INmune Bio (INMB) Overvalued in 2026?
Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued.
The current stock price of $1.36 is trading 26.4% below its estimated GF Value™ of $1.84.
GuruFocus considers INmune Bio to be Modestly Undervalued.
Key valuation signals for INMB:
EBITDA Margin %: 0.00%
GF Value™: $1.84 vs. price of $1.36 (26.4% below fair value)
No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
52GF Score
Get the complete analysis for INMB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INMB has been successfully added to your 
